Oncimmune and Genostics Company part ways in China

5 May 2021

Nottingham, UK-based immunodiagnostics specialist Oncimmune (AIM: ONC.L) has taken back certain intellectual property (IP) and distribution rights for its EarlyCDT technology.

The firm out-licensed Chinese rights to the platform to Genostics Company in January 2018, and the companies have collaborated since then with the goal of developing a lung panel with superior performance.

The use of EarlyCDT - a simple blood test that detects the elevated presence of autoantibodies generated by cancer - is particularly valuable in the region, given the prevalence of EGFR-positive non-small cell lung cancer (NSCLC).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK